Patents by Inventor Manoranjan PANDA

Manoranjan PANDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240199584
    Abstract: The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
    Type: Application
    Filed: August 16, 2023
    Publication date: June 20, 2024
    Inventors: Brian Edward Fink, Khehyong Ngu, Pravin S. Shirude, Manoranjan Panda, Prasada Rao Jalagam, Laxmi Narayan Nanda, Vishweshwaraiah Baligar, Balaji Seshadri, Excel Merlin Soosairaj, Maximilian David Palkowitz, Amit Kumar Chattopadhyay
  • Patent number: 11970511
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 30, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Publication number: 20230212158
    Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: May 10, 2021
    Publication date: July 6, 2023
    Inventors: Prasada Rao Jalagam, Susheel Jethanand Nara, Manoranjan Panda, Murugesan Natesan, Pratik Devasthale
  • Publication number: 20230192672
    Abstract: The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 22, 2023
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Susheel Jethanand Nara, Manoranjan Panda, Pratik Devasthale, Alicia Regueiro-Ren
  • Publication number: 20230167131
    Abstract: The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.
    Type: Application
    Filed: February 11, 2021
    Publication date: June 1, 2023
    Inventors: Kumaravel Selvakumar, Venkatram Paidi, Srinivasan Thangathirupathy, Vijaya Kumar Cm, Tirupathi Rao Alajangi, Mallikarjun Reddy Sura, Krishna Mahadevu, Ramesh Kumar Sistla, Piyush Agarwal, Arul Mozhi Subbiah Karuppiah, Jalathi S. Nair, Ooha Morampudi, Manoranjan Panda, Joseph A. Tino, Robert J. Cherney, John V. Duncia, Daniel S. Gardner, T. G. Murali Dhar, Audrey Graham Ross, Paul E. Gormisky, Xiao Zhu, Boris M. Seletsky, Alyssa H. Antropow, Deqiang Niu, Zhengdong Zhu, Guobin Miao, Julio Herman Cuervo
  • Patent number: 11639353
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: May 2, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • Publication number: 20230124468
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
    Type: Application
    Filed: October 5, 2022
    Publication date: April 20, 2023
    Inventors: Navnath Dnyanoba Yadav, Rajeev S. Bhide, Rajesh Onkardas Bora, Prashantha Gunaga, Manoranjan Panda, Eldon Scott Priestley, Jeremy Richter
  • Publication number: 20220144818
    Abstract: The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: April 8, 2020
    Publication date: May 12, 2022
    Inventors: Chunjian Liu, Jianxin Feng, Pratik Devasthale, Natesan Murugesan, Bruce A. Ellsworth, Alicia Regueiro-Ren, Susheel Jethanand Nara, Prasada Rao Jalagam, Manoranjan Panda
  • Patent number: 11267811
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Ramakanth Sarabu, Jacob Swidorski, Brett R. Beno, Alicia Regueiro-Ren
  • Publication number: 20210323991
    Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 21, 2021
    Inventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
  • Publication number: 20210246136
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 25, 2021
    Publication date: August 12, 2021
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • Patent number: 11072626
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: July 27, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Alicia Regueiro-Ren
  • Patent number: 11014922
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 25, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, Fang Moore, Guohua Zhao, Susan Nicole Pieniazek, Kumaravel Selvakumar, Suresh Dhanusu, Manoranjan Panda, Lawrence R. Marcin
  • Publication number: 20210147408
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: September 27, 2018
    Publication date: May 20, 2021
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Ramakanth SARABU, Jacob SWIDORSKI, Brett R. BENO, Alicia Regueiro-Ren
  • Patent number: 10851108
    Abstract: Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: December 1, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prashantha Gunaga, Jeremy Richter, Navnath Dnyanoba Yadav, Manoranjan Panda, Sreenivasulu Godesi
  • Patent number: 10829501
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Vladimir Ladziata, Indawati DeLucca, Donald J. P. Pinto, Michael J. Orwat, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Wu Yang, Scott A. Shaw, Peter W. Glunz, Manoranjan Panda
  • Publication number: 20200339550
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Navnath Dnyanoba Yadav, Rajeev S. Bhide, Rajesh Onkardas Bora, Prashantha Gunaga, Manoranjan Panda, Eldon Scott Priestley, Jeremy Richter
  • Publication number: 20200308213
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: October 10, 2018
    Publication date: October 1, 2020
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Alicia Regueiro-Ren
  • Patent number: 10723723
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prashantha Gunaga, Rajeev S. Bhide, Rajesh Onkardas Bora, Manoranjan Panda, Navnath Dnyanoba Yadav, Eldon Scott Priestley, Jeremy Richter
  • Patent number: RE49700
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is: each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: October 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Navnath Dnyanoba Yadav, Rajeev S. Bhide, Rajesh Onkardas Bora, Prashantha Gunaga, Manoranjan Panda, Eldon Scott Priestley, Jeremy Richter